Knight et al. have developed a mouse model that resembles the claudin-low subtype of triple-negative breast cancer (TNBC) by expressing a weakly oncogenic MET receptor tyrosine kinase under the control of the mouse mammary tumour virus promoter concomitant with conditionally deleting Trp53 in the mammary gland. Tumours in these mice have a similar molecular signature to human claudin-low TNBC, and require MET for proliferation and for maintaining the claudin-low morphological phenotype. Therefore, MET inhibitors may be effective against TNBC.
ORIGINAL RESEARCH PAPER
Knight, J. F. et al. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc. Natl Acad. Sci. USA 18 Mar 2013 (doi:10.1073/pnas.1210353110)
Rights and permissions
About this article
Cite this article
Seton-Rogers, S. Improving mouse models. Nat Rev Cancer 13, 295 (2013). https://doi.org/10.1038/nrc3524
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3524
